

1) Protecting all Fijians from COVID19

2) Reduce Mortality & Morbidty related to COVID19

3) Supporting the Economical Recovery for Fiji

Objective of the COVID19 Vaccines

Background

 Fiji received it's first batch of vaccines on the 6th of March- from the COVAX Facility:


• To date we have received:

- 12,000 (Covax)

- 100,000 (Covishield)

56,000 individuals

- 24,000 (Covax- short shelf life) – for 24,000 individuals (started roll out again just this week).




Question 1a: How did you design your COVID-19 vaccines strategy?

- i) Systems Approach from any immunization program
- ii) Guided template by the WHO & UNICEF with additions by MOHMS (Family Health Unit)
- iii) Three main oversight committees:
 - Interagency Coordinating Committee who acted as technical advisors to the MHMS
 - National Coordinating Committee made up of divisional medical and nursing heads
 - *****Communications Steering Committee

Question 1b: What were your main considerations in doing so?

- Regulatory authority
- ❖ Target Population
- Cold Chain
- Deployment
- Adverse Events Following Immunization
- ❖Digital Platform (Registration & Vaccination)
- ❖Financing
- ❖Communications etc.

Question 1c: How are you prioritizing populations for COVID-19 vaccines and why?



All individuals >18 years of age = $\sim 650,000$

(70% of Fiji Population)

Question 1d: Where do you anticipate procuring/ accessing vaccines from?

- i) Covax Facility
- ii) Government to Government Initiative (E.g India)
- iii) Procurement Manufacturers

Question 2a: What are your estimates of costs for providing coverage, and what are the main cost drivers?

- NDVP estimates for the four-tiered approach is FJD 22.85m
- The main cost drivers are:
 - Unsubsidized vaccine cost: FJD 13.8m (after the initial COVAX 20% coverage)
 - Vaccine Impact Assessment: FJD 3.16m
 - National roll-out operational costs: FJD 3.14m
 - Subsidized vaccines to reach 20% initial coverage: FJD 1.38m

Question 2b: How is your country/ does your country anticipate financing the vaccine coverage [external assistance, domestic health spending]?

* The vaccines are anticipated to be financed from COVAX and bilateral development partners

Question 2c: What challenges do you anticipate with planning and financing COVID-19 vaccine coverage?

- Specific Distribution Plan of COVAX/
- Global supply issue
- Increase in cases in specific sites for e.g India & PNG

Question 3a: What challenges do you anticipate with implementing the COVID-19 vaccine roll-out?

- i) Vaccines trickling in slowing into the country:
- affecting logistics issues on the ground
- ❖ A start and stop strategy.
- ii) Vaccines through the COVAX Facility delayed
- To a certain level unavoidable due to the supply demand issues globally
- iii) Positive cases of COVID19 in Fiji
- Strategy changes (suiting the situation)
- iv) Vaccine hesitancy
- Overcoming this through communications materials and demand creation

Question 3b: How does the COVID-19 vaccine roll-out affect your country's national immunization program and access to other essential services?

- Separation of teams doing normative and campaign services
- Human resource on the ground:
- i) More HR to my COVID19 vaccination team: (Specific teams for)
- a) Logistics
- b) AEFI
- c) Communications
- d) IT support
- ii) Involvement of Non-Government Organisations (Red Cross/MSP/RFHAF)

Vinaka Vakalevu- Thank you